Code · BILL · 116th Congress · H.R. 19 (Introduced in House) — To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the... · Sec. 393

Sec. 393. Conditions of use for biosimilar biological products

77 words·~1 min read·/bill/116/hr/19/ih/section-393

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

Section 351(k)(2)(A)(iii) of the Public Health Service Act ( 42 U.S.C. 262(k)(2)(A)(iii) ) is amended— in subclause (I), by striking ; and and inserting a semicolon; in subclause (II), by striking the period and inserting ; and ; and by adding at the end the following: may include information to show that the conditions of use prescribed, recommended, or suggested in the labeling proposed for the biological product have been previously approved for the reference product. .

Connectionstraces to 1

Traces to 1 document

U.S. Code

Regulation of biological products
§ 262

Citation graph

cites case law

Sec. 393

Conditions of use for biosimilar biological products

U.S.C.§ 262

Cites 1Cited by 0 across 0 sources